Small Molecules

20 Dec 2018 Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes
20 Dec 2018 Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
20 Dec 2018 Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
20 Dec 2018 AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
20 Dec 2018 Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
20 Dec 2018 Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia
20 Dec 2018 Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)
20 Dec 2018 Asana BioSciences Announces Initiation of First-in-Human Clinical Study with ASN008, a Novel Topical Product for the Treatment of Pruritus Associated with Atopic Dermatitis
20 Dec 2018 Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia
20 Dec 2018 UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
20 Dec 2018 Ayala Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study of Lead Product Candidate AL101 for Adenoid Cystic Carcinoma with Notch Activated Mutations
20 Dec 2018 Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
20 Dec 2018 Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck
20 Dec 2018 Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia
20 Dec 2018 Results of the Phase I Study of Repeated and Increasing Doses to Assess CER-209 in NASH/NAFLD
20 Dec 2018 LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
20 Dec 2018 Spirita Oncology Initiated Global Clinical Development of E6201 in Collaboration With JS InnoPharm (Shanghai) Under Strategic Partnership Alliance and Sub-license Agreement
20 Dec 2018 Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
19 Dec 2018 Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration
19 Dec 2018 Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML
19 Dec 2018 Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S
19 Dec 2018 Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug
19 Dec 2018 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
19 Dec 2018 Ascentage Pharma Announces Strategic Collaboration with Genor Biopharma
19 Dec 2018 Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up